Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 18;9(11):1575. doi: 10.3390/healthcare9111575

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

(a) PROs endpoints from the BREEZE-AD1, AD2, AD4, and AD7: Proportion of patients treated with baricitinib 4 mg achieving ≥4-point improvement in Itch NRS from baseline at W16 compared to placebo. Abbreviations: PBO, placebo; NRS, Numeric Rating Scale; W16, week 16; bari, baricitinib. * In BREEZE-AD4 and AD7, baricitinib was administered in association with topical corticosteroid as for protocol. (b) PROs endpoints from the BREEZE-AD1, AD2, AD4, and AD7: Change from Baseline to W16 in the Dermatology Life Quality Index (DLQI) in patients treated with baricitinib 4 mg compared to placebo. Abbreviations: PBO, placebo; DLQI, Dermatology Life Quality Index; W16, week 16; bari, baricitinib. * In BREEZE-AD4 and AD7, baricitinib was administered in association with topical corticosteroid as for protocol. (c) PROs endpoints from the BREEZE-AD1, AD2, AD4, and AD7: Change from Baseline to W16 in the in ADSS Item 2 in patients treated with baricitinib 4 mg compared to placebo. Abbreviations: PBO, placebo; ADSS, Atopic Dermatitis Symptom Score; W16, week 16; bari, baricitinib. * In BREEZE-AD 4 and AD7, baricitinib was administered in association with topical corticosteroid as for protocol.

(a) PROs endpoints from the BREEZE-AD1, AD2, AD4, and AD7: Proportion of patients treated with baricitinib 4 mg achieving ≥4-point improvement in Itch NRS from baseline at W16 compared to placebo. Abbreviations: PBO, placebo; NRS, Numeric Rating Scale; W16, week 16; bari, baricitinib. * In BREEZE-AD4 and AD7, baricitinib was administered in association with topical corticosteroid as for protocol. (b) PROs endpoints from the BREEZE-AD1, AD2, AD4, and AD7: Change from Baseline to W16 in the Dermatology Life Quality Index (DLQI) in patients treated with baricitinib 4 mg compared to placebo. Abbreviations: PBO, placebo; DLQI, Dermatology Life Quality Index; W16, week 16; bari, baricitinib. * In BREEZE-AD4 and AD7, baricitinib was administered in association with topical corticosteroid as for protocol. (c) PROs endpoints from the BREEZE-AD1, AD2, AD4, and AD7: Change from Baseline to W16 in the in ADSS Item 2 in patients treated with baricitinib 4 mg compared to placebo. Abbreviations: PBO, placebo; ADSS, Atopic Dermatitis Symptom Score; W16, week 16; bari, baricitinib. * In BREEZE-AD 4 and AD7, baricitinib was administered in association with topical corticosteroid as for protocol.